Amgen Inc. (NASDAQ:AMGN) Shares Bought by Prospera Financial Services Inc

Prospera Financial Services Inc lifted its position in Amgen Inc. (NASDAQ:AMGN - Free Report) by 28.1% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 30,373 shares of the medical research company's stock after purchasing an additional 6,662 shares during the quarter. Prospera Financial Services Inc's holdings in Amgen were worth $9,788,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in AMGN. Capital International Investors increased its stake in Amgen by 547.8% during the first quarter. Capital International Investors now owns 7,005,269 shares of the medical research company's stock worth $1,991,738,000 after acquiring an additional 5,923,915 shares during the last quarter. Pathway Financial Advisers LLC increased its stake in Amgen by 33,125.4% during the third quarter. Pathway Financial Advisers LLC now owns 4,460,181 shares of the medical research company's stock worth $1,437,115,000 after acquiring an additional 4,446,757 shares during the last quarter. International Assets Investment Management LLC increased its stake in Amgen by 6,812.4% during the third quarter. International Assets Investment Management LLC now owns 2,523,387 shares of the medical research company's stock worth $8,130,610,000 after acquiring an additional 2,486,882 shares during the last quarter. Janus Henderson Group PLC increased its stake in Amgen by 137.1% during the first quarter. Janus Henderson Group PLC now owns 2,381,133 shares of the medical research company's stock worth $676,984,000 after acquiring an additional 1,377,007 shares during the last quarter. Finally, Assenagon Asset Management S.A. increased its stake in Amgen by 561.5% during the third quarter. Assenagon Asset Management S.A. now owns 1,539,733 shares of the medical research company's stock worth $496,117,000 after acquiring an additional 1,306,982 shares during the last quarter. 76.50% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several brokerages have issued reports on AMGN. Truist Financial lowered Amgen from a "buy" rating to a "hold" rating and boosted their target price for the company from $320.00 to $333.00 in a research report on Monday, October 14th. William Blair restated an "outperform" rating on shares of Amgen in a research report on Tuesday, November 12th. StockNews.com upgraded Amgen from a "buy" rating to a "strong-buy" rating in a research report on Friday, November 1st. Barclays boosted their target price on Amgen from $300.00 to $315.00 and gave the company an "equal weight" rating in a research report on Monday, October 7th. Finally, Dbs Bank upgraded Amgen to a "strong-buy" rating in a research report on Monday, September 16th. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, eleven have given a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $333.57.

Amgen Stock Up 0.7 %

Shares of AMGN stock traded up $2.05 during trading hours on Tuesday, reaching $280.81. 1,480,096 shares of the company's stock were exchanged, compared to its average volume of 2,452,672. The stock's 50 day moving average is $319.90 and its 200-day moving average is $318.65. The company has a market cap of $150.94 billion, a price-to-earnings ratio of 35.69, a P/E/G ratio of 2.53 and a beta of 0.60. The company has a current ratio of 1.32, a quick ratio of 0.96 and a debt-to-equity ratio of 7.55. Amgen Inc. has a fifty-two week low of $260.52 and a fifty-two week high of $346.85.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share for the quarter, beating analysts' consensus estimates of $5.11 by $0.47. The firm had revenue of $8.50 billion for the quarter, compared to analyst estimates of $8.50 billion. Amgen had a net margin of 13.00% and a return on equity of 168.35%. Amgen's quarterly revenue was up 23.2% compared to the same quarter last year. During the same period last year, the company posted $4.96 EPS. Analysts predict that Amgen Inc. will post 19.51 earnings per share for the current fiscal year.

Amgen Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, December 9th. Investors of record on Monday, November 18th will be paid a $2.25 dividend. This represents a $9.00 dividend on an annualized basis and a yield of 3.21%. The ex-dividend date of this dividend is Monday, November 18th. Amgen's dividend payout ratio is presently 115.24%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.